Prof. Aru holds a Medical Oncology Consultant Hematology degree at the University of Indonesia. He is the President of The Indonesian Society of Oncology. He also serves on the Advisory Board of the Indonesian Internal Medicine Specialist Association (PB PAPDI). He is also a member of the Executive Board of the World Association of Internal Medicine, Executive Board Member of Indonesian Society of Hematology Medical Oncology (ISHMO), and Member of the Management of the Indonesian Cancer Foundation (YKI).

Dr. Bhawna Sirohi started her oncology career at Tata Memorial centre (TMC), Mumbai in 1994 and completed training at Royal Marsden NHS Foundation Trust, UK. She serves in BALCO Medical Centre as a Medical Director and is currently an honorary consultant with QMUL, London. At TMC in 2012-2014, she set up GI medical oncology &medical oncology information system (MOIS) for e-prescribing chemotherapy. She has been involved in initial setting up of cancer centres in Sangrur and Mohali, Punjab for TMC. She has piloted use of virtual consults using PROM & PREM in London.

Bradley G. Somer, MD, is a nationally-recognized expert in cancer care. His passion is his patients and their families. As President of West Cancer Center, Dr. Somer will lead projects such as sub-specialization and a new hospital rounding initiatives, while also serving as a leader in major projects, growth and expansion. Titles and Roles: Medical Oncologist, West Cancer Center President, West Cancer Center Associate Professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center Head of Strategic Expansion/Development, West Cancer Center. Dr. Somer is a senior partner at West Cancer Center and is part of the leadership team. Dr. Somer joined the West team in 2002 after completing his fellowship training at the University of Pennsylvania Cancer Center. Dr. Somer also completed his internship and residency at the Hospital University of Pennsylvania in Philadelphia. Board Certified in Medical Oncology, he sees patients in our Memphis, TN, and Southaven, MS, offices. Dr. Somer is actively involved in clinical research, often participating as principal investigator in research trials at West Cancer Center.

Dr. Changhoon Yoo is a medical oncologist who specializes in the care of patients with gastrointestinal cancers, particularly, pancreatic cancer, cholangiocarcinoma, hepatocellular carcinoma and neuroendocrine tumors. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with these cancers, and have authored and co-authored more than 80 research articles.

Dr. Chee is a clinician-investigator and medical oncologist in gastrointestinal and hepatobiliary cancers in NCIS. As the Programme Director for the NUHS Medical Oncology Senior Residency [Fellowship] Programme, she is actively involved in the education of the Medical Oncology trainees and she also chairs the Colorectal Cancer Committee of the Singapore Cancer Society

Dr Chok Aik Yong is a Colorectal Surgery Consultant at Singapore General Hospital. His Sub-specialties are in Colorectal Surgery, Inflammatory Bowel Disease, Endoscopy, Minimally Invasive Surgery – Laparoscopic Surgery

Dr. Clara Montagut is the Head of the Gastrointestinal Cancer Unit at Hospital del Mar, where she leads a team of clinical and translational research in novel therapies and biomarkers. Since 2012, Dr. Montagut is a professor at the Pompeu Fabra University. She is also working at Memorial Sloan Kettering Cancer Center on liquid biopsy and immunotherapy in colon cancer. Dr. Montagut has led and participated in many national and international clinical trials in gastrointestinal cancer, and has more than 50 publications in prestigious journals, including Nature Medicine, where she reported the discovery of a mutation of resistance to anti-EGFR therapy in colorectal cancer. Dr. Montagut is member of numerous national and international societies including the Spanish Association of Medical Oncology, the Spanish group of digestive tumors (TTD), the European Society of Medical Oncology (ESMO) and the American Association of Clinical Oncology (ASCO).

Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London. David leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation with highest honours at the University of Piemonte Orientale ""A. Avogadro"" in Novara, Italy. David completed his research training being awarded a Masters of Research in Translational Medicine and a Ph.D. in Clinical and Experimental Medicine. Whilst at Imperial as a research fellow and Ph.D. student he developed considerable experience in translational oncology within the specific setting of early phase clinical trials. As part of his ongoing collaboration with the academic pathology unit at Imperial, David devoted his research interests to the immune-phenotyping of malignancy. David's research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) twice in 2016 and 2017 as well as a third Merit Award jointly awarded by ASCO and by the Society for Immunotherapy of Cancer (SITC) in 2019. David was also awarded a prize by the British Society of Pharmacology in 2018 and the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016. David lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for a number of peer-reviewed journals including Hepatology, Journal of Hepatology, Oncogene, OncoImmunology and many others.

Dr Dawn Chong is a Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS) and specializes in gastrointestinal cancers. Dr Chong received the Singhealth Health Manpower Development Plan (HMDP) Fellowship award and completed a fellowship in clinical and translational cancer epidemiology at the Massachusetts General Hospital. She also received the National Medical Research Council (NMRC) Research Training Fellowship and obtained a degree in Master of Public Health at the Harvard T.H. Chan School of Public Health. Dr Chong's research focuses on cancer epidemiology, with the aim of critical analyses of epidemiologic exposures with clinical and genetic information to elucidate novel biomarkers that can be used to risk stratify patients and guide treatment decisions. She was awarded the NMRC Transition Award for her research on metabolites in colorectal cancer. She has published in many high impact journals including JAMA Oncology and Lancet Oncology. Dr Chong is an Assistant Professor of the Duke-NUS Graduate Medical School and a clinical lecturer of the Yong Loo Lin Medical School. She has been actively involved in the training of undergraduates and young clinicians.

Professor Do-Youn Oh is a medical oncologist practicing at Seoul National University Hospital. Prof. Oh graduated top of her class from Seoul National University College of Medicine in 1997, and completed residency training in Internal Medicine, as well as a fellowship in Hematology/Medical Oncology in Seoul National University Hospital. Following which, Prof. Oh obtained her Ph.D. degree in the Department of Internal Medicine, Seoul National University College of Medicine in 2005. Prof. Oh’s main research interests lie in gastric cancer, pancreatic cancer and biliary tract cancer with a particular interest in the translational research and early new drug development. From early on, she had been awarded numerous awards, including the Young Investigator Award from the Korean Association for Clinical Oncology in 2013. Prof. Oh is actively conducting clinical trials including phase I-3 studies and First-in-Human studies with the aim of developing new anticancer drugs to improve patients' survival. She has published over 300 peer-reviewed journal articlesProf. Oh’s professional affiliations include memberships in the Korean Cancer Association, Korean Association for Clinical Oncology, Korean Cancer Study Group, American Society of Clinical Oncology and American Association for Cancer Research.

Dr. Eileen is medical oncologist whose research and clinical activities focus on treating pancreatic and hepatobiliary cancers. Dr. Eileen’s research initiatives include integrating molecular and genetic-based therapies into the treatment of pancreas cancer, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. Dr. Eileen is the principal investigator of multiple phase I, II, and III pancreatic cancer clinical trials and have authored and co-authored more than 250 articles, editorials, and book chapters.

Dr Faye Lim graduated from the University of Nottingham Medical school and completed her Clinical Oncology Training at Mount Vernon Cancer Centre and University College Hospital. She is a senior consultant in the department of radiation oncology at the National Cancer Centre Singapore Her sub specialty includes breast and gastrointestinal cancers. She has a particular interest in the use of proton therapy in the treatment of breast cancer.

Professor Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. After obtaining his undergraduate degree in Biology, he then went on to earn his medical degree at the American University in Beirut (AUB). He later completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, and received his MBA from Columbia University. As a medical oncologist, Prof. Abou-Alfa specializes in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC). Prof. Abou-Alfa is a member of the International Affairs Committee of the American Society of Clinical Oncology (ASCO) and serves as a member of its Steering Committee. He is also the President for the International Society of Gastrointestinal Oncology (ISGIO). His key research interest focuses on improving the effectiveness of cancer therapy by incorporating small novel biological molecules that target cancer into the treatment of chemotherapy-resistant gastrointestinal malignancies, particularly hepatobiliary and pancreatic cancers.

Dr. Han Shuting is a Consultant at the Department of Medical Oncology in National Cancer Centre Singapore. She graduated with Bachelor of Arts (Honours) from Christ’s College, Cambridge in 2010 and Bachelor of Medicine and Surgery (MBBChir) from Cambridge School of Clinical Medicine in 2013. Subsequently, she obtained her MRCP (UK) and MMed (Int. Med) accreditation in 2015. She completed her medical oncology training in National Cancer Centre (Singapore) in 2019.

Dr. Iain Tan is a Senior Consultant Medical Oncologist, leading the colorectal cancer service in the GI Oncology Team at the Department of Medical Oncology, National Cancer Centre Singapore. Dr Iain Tan, a clinician-scientist at A*STAR’s Genome Institute of Singapore (GIS), was awarded the prestigious Singapore Youth Award 2014. Dr Tan has been recognized for his contributions as a consultant oncologist at the National Cancer Singapore (NCCS) and research scientist at GIS, and for his efforts to cultivate an environment conducive for translational research. Dr Tan’s research focuses on new ways in the early detection and diagnosis of colorectal cancer.

Skilled in Clinical Research, Medical Education, Life Sciences, Haemato-Oncology, and Medicine. Strong healthcare professional focused on Medical Oncology including Haemato-Oncology, medical education and clinical research. Senior Consultant Medical Oncologist at Tan Tock Seng Hospital. Director, Clinical Trials, CRIO & Co-Director (TTSH) PHFRC. Adj/Asst Prof at LKC School of Medicine. Asst Professor of Oncology Johns Hopkins University. His clinical interests include Thoracic Cancers, Gastrointestinal Cancers, Head & Neck Cancers, HIPEC, Sarcomas, Genitourinary Cancers, and Lymphomas. Cancer Genetics and Clinical Research Trials

Dr. Shiu is a Consultant in the Gastrointestinal Oncology Unit at University College London Hospital NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Institute. His research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, as well as the development of novel cancer clinical trial designs. He is the Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank and member of ASCO, ESMO and the Chair of the Association of Cancer Physicians New Consultant Group.

Kei Muro, MD, PhD is chief and director of the Department of Clinical Oncology and Outpatient Treatment Center at Aichi Cancer Center Hospital in Nagoya, Japan. In addition, he has been also promoted to deputy director in Aichi Cancer Center Hospital at 2018. Dr. Muro graduated medical school in 1990 from the University of Tohoku and completed internal medicine training at the Iwaki Kyoritsu Hospital in 1993. He completed a residency in gastrointestinal oncology in the Digestive Endoscopy Division at the National Cancer Center Hospital East in 1997, and has been a staff doctor in the Gastrointestinal Oncology Division at the National Cancer Center Hospital since 1997. He is an adjunct professor at Nagoya University Graduate School of Medicine and Tokyo University Graduate School of Medical Science, and is an adjuvant and clinical professor at Nagoya City University Graduate School of Medical Science. He got the Degree of Doctor of Philosophy (Medical Science), Yokohama City University in 2021 Dr. Muro is an executive board member of the Japanese Society of Medical Oncology, Japanese Gastric Cancer Association. In addition, he is also council member of Japan Esophageal Society, Japan Society of Coloproctology, and Japanese Cancer Association. He is a member of American Society of Clinical Oncology, and faculty member for gastrointestinal tumors in European Society of Medical Oncology (2017-2021). He collaborates with the World Health Organization on the Japanese Gastric Cancer Committee. In terms of clinical trial activity, he is a chair of gastrointestinal cancer group in West Japan Oncology Group. He is also a reviewer for the Japanese Journal of Clinical Oncology and Esophagus. Furthermore, he was awarded the Nagoya International Cancer Treatment Symposium BMS Award in 2012 and was also awarded Excellent Presentation Award of the Japan Society of Clinical Oncology in 2013. He is the author of more than 370 peer review journals.

Dr Koh Ye Xin is a Consultant at the Department of Hepato-pancreato-biliary and Transplant Surgery in Singapore General Hospital and a member of the Singapore Hepato-Pancreato-Biliary Association (HPBA-S). Dr Koh serves as the Co-Chairman of the Quality Improvement Committee of the Surgery Academic Clinical Programme. Dr Koh graduated from the SingHealth General Surgery Residency Programme and the Singapore Chief Residency Programme from the Healthcare Leadership College. Dr Koh is a Fellow of the Royal College of Surgeons, Edinburgh and holds a Master of Medicine (Surgery). He was the Asia-Pacific awardee of the Japan Hepato-Pancreato-Biliary Society observership to Hokkaido University for training in advanced hepato-pancreato-biliary malignancy. He was a senior clinical fellow in Abdominal Transplantation at Cambridge University, Addenbrookes hospital, focusing on multivisceral and intestinal transplantation.

Dr Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. He received his medical degree from Tohoku University School of Medicine in 2002. Dr Shitara is an active member of ASCO and ESMO. He is also a member of the Japanese Society of Internal Medicine, the Japanese Society of Medical Oncology (JSMO), the Japanese Society of Clinical Oncology (JSCO), the Japanese Gastric Cancer Association, Protocol Review Committee of Japanese Clinical Oncology Group (JCOG), West Japanese Oncology Group (WJOG). He also acts as one of the organising members for Japanese gastric cancer treatment guidelines. Main research interests include development of new anti-cancer agents, optimal chemotherapy regimen for gastrointestinal cancer, and translational research. He is the primary investigator or study coordinator of several sponsor initiated trials or investigator initiated trials for gastric or colorectal cancer: He act as a steering committee members of 5 global studies in the field of GI cancers. He also acts as a study coordinator of the Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN). He has reported 120 peer review publications which include approximately 80 articles as 1st author or corresponding author in these fields.

Dr Maria Tamayo is a Medical Oncologist from the Philippines. She is a part of the Philippine Society of Medical Oncology [PSMO]. Maria Belen Tamayo is also the Co -Director at Makatimed Cancer Center; The Medical City.

Dr. Matthew NG is a medical oncologist with research interest in gastrointestinal cancers and experimental therapeutics.He completed his PhD from the Institute of Cancer Research (London). Currently he is the oncology lead for upper GI cancers and Deputy Director of the Investigational Medicine Unit at National Cancer Centre Singapore. His research interest is to develop novel therapeutic strategies for patients particularly in gastrointestinal cancers.

Prof. Pierce Chow is a senior consultant and Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore, Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital and Professor and Course Director at Duke-NUS Medical School Singapore. In addition to managing a busy HPB surgical oncology service, Prof. Chow has researched extensively on hepatocellular carcinoma (HCC). He leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine.

Dr Raghav Sundar is a Consultant Medical Oncologist specialising in Gastrointestinal cancers and early phase clinical trials. His clinical interest is in gastrointestinal cancers. His research interest lies in early phase drug development, immunotherapy, DNA damage repair, and chemotherapy-induced neuropathy. He has published in high impact peer-reviewed journals including Cancer Discovery and Clinical Cancer Research and designs clinical trials for novel cancer drugs.

Dr Shaheenah Dawood is a Consultant Medical Oncologist and Professor in Clinical Oncology in the United Arab Emirates. She was trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training, she was awarded multiple scholar training awards besides ASCO merit awards. Dr Shaheenah has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles, and 12 book chapters. Having served as a reviewer for multiple journals including the Journal of Clinical Oncology she is currently leading the oncology clinical trials program at Mediclinic City Hospital, Dubai. She also serves as President of Excellence in Oncology Care (EIOC) annual congress held in Dubai and is Co-Chair of the Asia Pacific Breast Cancer Summit (APBCS), Asia Pacific Gastrointestinal Cancer Summit (APGCS) ,the international BRCA forum (iBRCAf) and Young Women Forum (YWF) from over a decade.

Professor Shailesh V. Shrikhande is a Gastrointestinal Cancer Surgeon from Mumbai, India. He has over two decades of experience with special interest in Pancreatic Cancer surgery. He is the Deputy Director of Tata Memorial Hospital in Mumbai and also the Head of Division Cancer Surgery and Chief of GI and HPB Surgery. He is the President of the Indian Chapter of IHPBA 2019 – 2021 and Scientific Committee Chair of IHPBA 2019-2021.

Dr. Stephen L. Chan is the Associate Clinical Professor of the Department of Clinical Oncology in the Chinese University of Hong Kong. He graduated from the University of Hong Kong in 2000 and obtained specialist qualification in Medical Oncology in 2007. He has been awarded the Gold Medal Prize for Dissertation in 2007 and Young Investigator award in 2008 by the Hong Kong College of Physician. His main research area is on clinical and traditional researches for gastrointestinal cancers, especially hepatobiliary and pancreatic cancers.

Dr. Sayed Md. Akram Hussain graduated MBBS from Dhaka University, Bangladesh (studied with merit scholarship from Bangladesh Govt.) on year 1990. Later on 2000, he achieved residency in Radiation Oncology at National Institute of Cancer Research and Hospital Fellow (Radiation Oncology) of Bangladesh College of Physicians and Surgeons (BCPS). He accomplished Masteras of Public Health (Epidemiology), from New Castle University, USA on year 2005 and Mastera of Public Health (Clinical Epidemiology), from Atish Dipankor Science & Technology University, Dhaka, Bangladesh on year 2010. He also took Fellow of College Physicians and Surgeons of Glasgow from UK on year 2010 & Fellow of College Physicians of Edinburgh, UK on year 2011. He has expertise on IMRT, IGRT, Gating System, CT, MRI Simulation and Brach therapy. He is currently working as Professor and Head of the Department of Oncology at North East Medical College.

Dr. Takayuki Yoshino, M.D. PhD. currently works at the National Cancer Center Hospital East (NCCE) in Chiba, Japan, where he is the Director for the Department of Gastroenterology and Gastrointestinal Oncology and the Head of the Clinical Research Coordinating Division. He has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer (CRC), where he focuses on various investigational new agent and translational research. Dr. Yoshino received his medical degree from the National Defense Medical College and after completing his first residency there, he moved to the NCCE where he specialized in gastrointestinal oncology. He later spent five years at the Shizuoka Cancer Center and during this time, he studied in the USA at several world-renowned institutions, including the Mayo Clinic, Dana-Farber Cancer Institute and the Vanderbilt-Ingram Cancer Center. In 2007 Dr. Yoshino returned to the NCCE and has had over 150 peer-review scholar journal publications on metastatic CRC (mCRC), with several articles published in the Lancet Journal, Journal of Clinical Oncology, and the New England Journal of Medicine. In addition, he holds several professional appointments, serving on an international guideline member of the European Society for Medical Oncology (ESMO), a chair of Pan-Asian adapted ESMO Guideline for mCRC, a guideline member of the Japanese Society for Cancer of the Colon and Rectum and an international affairs committee member of the Japanese Society of Medical Oncology as well the administrative board for The Japanese Association for Molecular Target Therapy of Cancer.

Dr Tan is a Consultant Surgeon with the Department of Hepatopancreatobiliary and Transplant Surgery. Dr Tan’s clinical practice is focused on abdominal organ transplantation and conditions involving the liver, pancreas, and biliary tract. He adopts a collaborative multi-disciplinary approach to deliver individualized care to each patient. His clinical efforts are directed primarily at improving outcomes after organ transplantation, and in the treatment of advanced cancer. He is committed to an academic surgical practice, with active interests in tumour biology, immunology, and novel therapeutics in the treatment of cancer. He also has research interests in health policy and data analytics, which he believes can guide decision-making for clinicians to improve healthcare standards. He is engaged in medical education and the training of budding surgeons through the use of technology and adaptive learning methods.

Dr Toh is Senior Consultant and Deputy Chief Executive Officer (Strategic Partnerships), Division of Medical Oncology, National Cancer Centre Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston USA, and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. He is also an alumni at the Harvard Business School General Management Program. Dr Toh is a recipient of the National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer. He leads the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunologY) grant. As an Associate Professor and College Master at the Duke-NUS Graduate Medical School, Dr Toh is actively involved in medical education and training. He is the founding Chairman of the Singapore Society of Oncology Cancer Immunotherapy Consortium, co-founder of the Asia Pacific Gastroenterology Cancer Summit (APGCS), and faculty in the Cancer Immunology for the European Society of Medical Oncology (ESMO). Dr Toh has published over 132 peer review journal papers to date.

Associate Prof. Dr. Wan Zamaniah is a Consultant Clinical Oncologist at the University Malaya Medical Centre and University Malaya Specialist Centre, Kuala Lumpur, Malaysia. She graduated from University of Malaya, Kuala Lumpur Malaysia with Bachelor of Medicine & Bachelor of Surgery in 2001. Upon completion of her specialist training in clinical oncology in 2010 at the University of Malaya she joined University Malaya as a lecturer. She is a supervisor and coordinator for Master of Clinical Oncology programme as well as the University Malaya Medical programme at the Faculty of Medicine, UM. She is also actively doing research in clinical oncology field. She is also a council member of Malaysian Oncological Society, an Asia Pacific Regional council member for American Society of Clinical Oncology, a member of Academy of Medicine Malaysia, European Society for Medical Oncology and member of European Society of Radiation Oncology. Her areas of special interest include gastrointestinal cancers, head and neck cancers, gynaecological cancers and thyroid cancer. She is principle investigator for several international clinical trials mainly in gastrointestinal cancers and head and neck cancers. She published some of her works in the areas involved. She speaks in her areas of interest in both local and international scientific conferences.

Dr Wong Seng Weng is currently the Medical Director and Consultant Medical Oncologist of The Cancer Centre (Singapore Medical Group) at the Paragon and Mount Elizabeth Novena Specialists’ Centres. Apart from pursuing his clinical practice, Dr Wong was keenly involved as an investigator in over twenty clinical trials exploring novel methods of cancer treatment. He previously held the posts of Consultant Medical Oncologist and Senior Partner of the Raffles Cancer Centre in charge of all oncology services at the Raffles Hospital. He was also appointed as Chairman of the Singapore Medical Group Medical Board. Apart from his practice at The Cancer Centre, Dr Wong is currently also a visiting consultant of the National University Hospital where he is a tutor for medical oncologists-in-training. He is a visiting consultant medical oncologist of Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Mount Alvernia Hospital and Raffles Hospital. In the area of research, he holds the appointment of Adjunct Clinician Scientist of the Institute of Bioengineering and Nanotechnology (IBN) in the Agency for Science, Technology and Research (A*STAR). Dr Wong is part of the editorial advisory board of the oncology newspaper Oncology Tribune. Dr Wong is an active member of the American Society of Clinical Oncology (ASCO) as well as the European Society for Medical Oncology (ESMO) and Singapore Society of Oncology. He lectured widely at international cancer conferences in Vietnam, China, India, Bangladesh, Malaysia and Indonesia. Dr Wong specializes in the diagnosis and treatment of adult cancers with special interest in breast cancers, lung cancers and gastrointestinal cancers.

Dr Yong Wei Peng obtained his medical degree and postgraduate training in University of Aberdeen, Scotland. After completing an oncology fellowship at the National University Hospital, he was awarded the A*STAR International Fellowship in clinical pharmacology at the University of Chicago. Upon his return to Singapore, he was awarded a three-year Investigatorship Award under the Clinician Scientist Award to further his research into personalized therapy. Dr Yong leads the therapeutic arm (NUH module) of the Singapore Gastric Cancer Consortium. The consortium received the prestigious five-year Translational Clinical Research grant in 2007. He is also the Chairman of the National Healthcare Group Domain-Specific Ethics Review Board. His clinical interest is in gastrointestinal cancers and his research interests are pharmacogenetics and epigenetics in cancer.